Best of ASCO 2021-bladder cancer

被引：1
作者：
Mayrhofer, Karl [1 ]
Niedersuess-Beke, Dora [1 ]
机构：
[1] Klin Ottakring, Ctr Oncol Hematol & Palliat Care, Vienna, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2021年 / 14卷 / 04期
关键词：
Bladder preservation; Immunotherapy; Pembrolizumab; Durvalumab tremelimumab; Multimodal treatment; PEMBROLIZUMAB PEMBRO; UROTHELIAL CANCER; MIBC; GEMCITABINE; CISPLATIN; NIVOLUMAB; TRIAL; RT;
D O I：
10.1007/s12254-021-00765-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Three trials presented at the meeting investigated the incorporation of immunotherapy into a multimodal bladder-sparing treatment approach. The results of these phase 2 trials are so far promising with most patients achieving complete remission (CR) and estimated bladder-intact disease-free survival (BIDFS) in these patients ranges between 73 and 88%. Additionally, the up to 5-year follow-up data from the KEYNOTE-052 study were discussed. The results confirm the efficacy of pembrolizumab as first-line monotherapy in cisplatin-ineligible patients with a programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 10.
引用
收藏
页码：335 / 337
页数：3
相关论文
共 6 条
  • [1] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
    Bajorin, D. F.
    Witjes, J. A.
    Gschwend, J. E.
    Schenker, M.
    Valderrama, B. P.
    Tomita, Y.
    Bamias, A.
    Lebret, T.
    Shariat, S. F.
    Park, S. H.
    Ye, D.
    Agerbaek, M.
    Enting, D.
    McDermott, R.
    Gajate, P.
    Peer, A.
    Milowsky, M., I
    Nosov, A.
    Antonio Jr, J. N.
    Tupikowski, K.
    Toms, L.
    Fischer, B. S.
    Qureshi, A.
    Collette, S.
    Unsal-Kacmaz, K.
    Broughton, E.
    Zardavas, D.
    Koon, H. B.
    Galsky, M. D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) : 2102 - 2114
  • [2] Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
    Balar, Arjun Vasant
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Alva, Ajjai Shivaram
    Kollmeier, Marisa
    Rose, Tracy L.
    Pitroda, Sean
    Kaffenberger, Samuel D.
    Rosenberg, Jonathan E.
    Francese, Kaitlyn
    Hochman, Tsivia
    Goldberg, Judith D.
    Griglun, Sarah
    Leis, Dayna
    Steinberg, Gary D.
    Wysock, James
    Schiff, Peter B.
    Sanfilippo, Nicholas J.
    Taneja, Samir
    Huang, William C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
    Galsky, Matt D.
    Daneshmand, Siamak
    Chan, Kevin G.
    Dorff, Tanya B.
    Cetnar, Jeremy Paul
    Neil, Brock O.
    D'souza, Anishka
    Mamtani, Ronac
    Kyriakopoulos, Christos
    Garcia, Philip
    Izadmehr, Sudeh
    Yu, Menggang
    Zhao, Qianqian
    Mehrazin, Reza
    Lewis, Sara C.
    Sfakianos, John
    Pal, Sumanta K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
    Garcia del Muro, Xavier
    Valderrama, Begona P.
    Medina, Ana
    Andres Cuellar, M.
    Etxaniz, Olatz
    Girones Sarrio, Regina
    Jose Juan-Fita, Maria
    Ferrer, Ferran
    Miras Rodriguez, Isabel
    Lendinez-Cano, Guillermo
    de Haro Piedra, Roberto
    Candal Gomez, Arturo
    Chantada Abal, Venancio
    Salvador Villa, Oscar Buisan
    Luis Pontones, Jose
    Collado, Erica
    Dominguez-Escrig, Jose L.
    Murria, Yashmina
    Vigues, Francesc
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
    O'Donnell, Peter H.
    Balar, Arjun Vasant
    Vuky, Jacqueline
    Castellano, Daniel
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Grivas, Petros
    Hahn, Noah M.
    Plimack, Elizabeth R.
    Xu, Jin Zhi
    Godwin, James Luke
    Moreno, Blanca Homet
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
    Powles, Thomas
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Valderrama, Begona P.
    Gurney, Howard
    Kalofonos, Haralabos
    Radulovic, Sinisa
    Demey, Wim
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Kopyltsov, Evgeny
    Sternberg, Cora N.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel P.
    Laliberte, Robert
    Wang, Jing
    Huang, Bo
    Davis, Craig
    Fowst, Camilla
    Costa, Nuno
    Blake-Haskins, John A.
    di Pietro, Alessandra
    Grivas, Petros
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13) : 1218 - 1230
1